VolitionRX Ltd. has released a new presentation highlighting its recent commercial progress and developments in both animal and human health sectors. The company has successfully launched its Nu.Q® Vet Cancer test in over 20 countries, selling approximately 120,000 tests and test components in 2024. The total addressable market for this sector is estimated to exceed $750 million. Additionally, VolitionRX has received $23 million in upfront and milestone payments, with an anticipated additional $5 million milestone payment related to feline health. The presentation also discusses the company's ongoing international partnerships and the significant opportunities in human health, including lung cancer screening and sepsis testing, which represent multi-billion dollar markets. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.